[{"orgOrder":0,"company":"Akshaya Bio","sponsor":"Cytovance Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Akshaya Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Akshaya Bio \/ Cytovance Biologics ","highestDevelopmentStatusID":"6","companyTruncated":"Akshaya Bio \/ Cytovance Biologics "}]

Find Clinical Drug Pipeline Developments & Deals by Akshaya Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Collaboration to focus on using Akshaya’s proprietary Chimigen® Platform Technology to execute bulk drug products of both COVID-19 and HBV vaccines to be used in Phase I clinical trials by Cytovance.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          April 23, 2020

                          Lead Product(s) : COVID-19 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Cytovance Biologics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank